

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|------------------------------------|--------------------------------|--|---------------------------|----------------------------|------------------------------------|
| J9264 | Abraxane | Paclitaxel Protein-Bound | Injection, Paclitaxel protein-bound particles, 1 mg | PA Request | 1/1/2024 | Oncology |
| J3262 | Actemra | Tocilizumab | Injection, Tocilizumab, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J0791 | Adakveo | Crizanlizumab-Tmca | Injection, Crizanlizumab-tmca, 5 mg | PA Request | 4/1/2023 | Sickle Cell Disease |
| J9042 | Adcetris | Brentuximab | Injection, Brentuximab Vedotin, 1 mg | PA Request | 4/1/2023 | Oncology |
| J0172 | Aduhelm | Aducanumab-Avwa | Injection, Aducanumab-avwa, 2 mg | PA Request | 4/1/2023 | Antidementia Agent |
| J1454 | Akynzeo | Fosnetupitant and Palonosetron | Injection, Fosnetupitant 235 mg and Palonosetron 0.25 mg | PA Request | 1/1/2024 | Anti-emetic |
| J0220 | Alglucosidase Alfa | Alglucosidase Alfa | Injection, Alglucosidase alfa, 10 mg | PA Request | 4/1/2023 | Enzyme Deficiency |
| J9305 | Aimta | Pemetrexed | Injection, Pemetrexed, not otherwise specified, 10 mg | PA Request | 1/1/2024 | Oncology |
| J2469 | Aloxi | Palonosetron | Injection, Palonosetron hcl, 25 mcg | No PA/No Precert Required | N/A | Anti-emetic |
| J9057 | Aliqopa | Copanlisib | Injection, Copanlisib, 1 mg | PA Request | 4/1/2023 | Oncology |
| J1426 | Amondys 45 | Casimersen | Injection, Casimersen, 10 mg | PA Request | 1/1/2023 | Duchenne Muscular Dystrophy (DMD) |
| C9145 | Aponvie | Aprepitant | Injection, Aprepitant, (Aponvie), 1 mg | No PA/No Precert Required | N/A | Anti-emetic |
| J2430 | Aredia | Pamidronate | Injection, Pamidronate disodium, per 30 mg | No PA/No Precert Required | N/A | Osteoporosis |
| J0225 | Amvuttra | Vutrisiran | Injection, Vutrisiran, 1 mg | PA Request | 8/1/2023 | RNAi Therapy (hATTR amyloidosis) |
| J9302 | Arzerra | Ofatumumab | Injection, Ofatumumab, 10 mg | PA Request | 4/1/2023 | Oncology |
| J9035 | Avastin | Bevacizumab | Injection, Bevacizumab, 10 mg | PA Request | 4/1/2023 | Oncology |
| Q5121 | Avsola | Infliximab-Axxq | Injection, Infliximab-Axxq, biosimilar, (Avsola), 10mg | PA Request | 8/1/2023 | Auto-Inflammatory Conditions |
| J9036 | Belrapzo | Bendamustine | Injection, Bendamustine hydrochloride, (Belrapzo/Bendamustine), 1 mg | PA Request | 1/1/2024 | Oncology |
| J9034 | Bendeka | Bendamustine | Injection, Bendamustine hcl (Bendeka), 1 mg | PA Request | 1/1/2024 | Oncology |
| J0490 | Benlysta IV | Belimumab | Injection, Belimumab, 10 mg | PA Request | 4/1/2023 | Systemic Lupus Erythematosus (SLE) |
| J0179 | Beovu | Brolucizumab | Injection, Brolucizumab-dbli, 1 mg | PA Request | 4/1/2023 | Macular Degeneration |
| C9142 | Bevacizumab (Alymsys) | Bevacizumab-maly | Injection, Bevacizumab-maly, biosimilar, (Alymsys), 10 mg | No PA/No Precert Required | N/A | Oncology |
| Q5126 | Bevacizumab (Alymsys) | Bevacizumab-maly | Injection, Bevacizumab-maly, biosimilar, (Alymsys), 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9229 | Besponsa | Inotuzumab Ozogamicin | Injection, Inotuzumab ozogamicin, 0.1 mg | PA Request | 4/1/2023 | Oncology |
| J1740 | Boniva | Ibandronate | Injection, Ibandronate sodium, 1 mg | No PA/No Precert Required | N/A | Osteoporosis |
| J9039 | Blincyto | Blinatumomab | Injection, Blinatumomab, 1 microgram | PA Request | 4/1/2023 | Oncology |
| J0585 | Botox | Onabotulinumtoxin | Injection, Onabotulinumtoxin, 1 unit | PA Request | 4/1/2023 | Neurotoxin |
| J0567 | Brineura | Cerliponase Alfa | Injection, Cerliponase alfa, 1 mg | PA Request | 4/1/2023 | Enzyme Deficiency |
| J2329 | Briumvi | Ublituximab-Xiyy | Injection, Ublituximab-xiyy, 1mg | PA Request | 1/1/2024 | Multiple Sclerosis |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|---------------------------------|----------------------------------|---|---------------------------|----------------------------|-------------------------------|
| Q5124 | Byooviz | Ranibizumab-Nuna | Injection, Ranibizumab-nuna, biosimilar, (Byooviz), 0.1 mg | PA Request | 8/1/2023 | Macular Degeneration |
| Q5128 | Cimerli | Ranibizumab-Eqrn | Injection, Ranibizumab-eqrn (Cimerli), biosimilar, 0.1 mg | No PA/No Precert Required | N/A | Macular Degeneration |
| J1786 | Cerezyme | Imiglucerase | Injection, Imiglucerase, 10 units | PA Request | 4/1/2023 | Enzyme Deficiency |
| J0717 | Cimzia | Certolizumab | Injection, Certolizumab Pegol, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J2786 | Cinqair | Reslizumab | Injection, Reslizumab, 1 mg | PA Request | 4/1/2023 | Asthma |
| J9999 | Columvi | Glofitamab-Gxbm | Glofitamab-gxbm | PA Request | 1/1/2024 | Oncology |
| J0584 | Crysvita | Burosumab | Injection, Burosumab-twza 1 mg | PA Request | 4/1/2023 | Metabolic Conditions |
| J1551 | Cutaquig | Immune Globulin | Injection, Immune Globulin (Cutaquig), 100 mg | PA Request | 1/1/2024 | Immunodeficiency |
| J1555 | Cuvitru | Immune Globulin | Injection, Immune Globulin (Cuvitru), 100 mg | PA Request | 1/1/2024 | Immunodeficiency |
| J9308 | Cynamza | Ramucirumab | Injection, Ramucirumab, 5 mg | PA Request | 4/1/2023 | Oncology |
| J9348 | Danyelza | Naxitamab-Gqgk | Injection, Naxitamab-gqgk, 1 mg | PA Request | 4/1/2023 | Oncology |
| J9145 | Darzalex | Daratumumab | Injection, Daratumumab 10 mg | PA Request | 4/1/2023 | Oncology |
| J9144 | Darzalex Faspro | Daratumumab / Hyaluronidase-Fihj | Injection, Daratumumab, 10 mg and hyaluronidase-fihj | PA Request | 4/1/2023 | Oncology |
| J7318 | Durolane | Hyaluronan Or Derivative | Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg | PA Request | 4/1/2023 | Osteoarthritis |
| J0586 | Dysport | Abobotulinumtoxina | Injection, Abobotulinumtoxina, 5 units | PA Request | 4/1/2023 | Neurotoxin |
| J9063 | Elahere | Mirvetuximab Soravtansine-Gynx | Injection, Mirvetuximab Soravtansine-gynx, 1 mg | PA Request | 1/1/2024 | Oncology |
| J1743 | Elaprase | Idursulfase | Injection, Idursulfase, 1 mg | PA Request | 11/1/2023 | Enzyme Deficiency |
| J3060 | Elelyso | Taliglucerase Alfa | Injection, Taliglucerase alfa, 10 units | PA Request | 4/1/2023 | Enzyme Deficiency |
| J9217 | Eligard | Leuprolide Acetate | Leuprolide acetate (for depot suspension) | PA Request | 1/1/2024 | Oncology |
| J9269 | Elzonris | Tagraxofusp-erzs | Injection, Tagraxofusp-erzs, 10 micrograms | PA Request | 11/1/2023 | Oncology |
| J9176 | Empliciti | Elotuzumab | Injection, Elotuzumab, 1mg | PA Request | 4/1/2023 | Oncology |
| J1438 | Enbrel | Etanercept | Injection, Etanercept, 25 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J9358 | Enhertu | Fam-Trastuzumab Deruxtecan-Nxki | Injection, Fam-trastu deru-nxki 1mg | PA Request | 4/1/2023 | Oncology |
| J1302 | Enjaymo | Sutimlimab-Jome | Injection, Sutimlimab-jome, 10 mg | PA Request | 1/1/2024 | Cold Agglutinin Disease (CAD) |
| J3380 | Entyvio | Vedolizumab | Injection, Vedolizumab, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J9999 | Epkiny | Epcoritamab-Bysp | Epcoritamab-bysp | PA Request | 1/1/2024 | Oncology |
| J0885 | Epogen/Procrit | Epoetin Alfa | Injection, Epoetin Alfa, (for non-ESRD use), 1000 units | PA Request | 4/1/2023 | Anemia |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|--------------|--------------------------------|--------------------------|--|---------------------------|----------------------------|-----------------------------------|
| Q4081 | Epogen/Procrit | Epoetin Alfa | Injection, Epoetin Alfa, 100 units (for ESRD on dialysis) | PA Request | 4/1/2023 | Anemia (Dialysis) |
| J7323 | Euflexxa | Hyaluronan or derivative | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | No PA/No Precert Required | N/A | Osteoarthritis |
| J9055 | Erbix | Cetuximab | Injection, Cetuximab, 10 Mg | PA Request | 4/1/2023 | Oncology |
| J3111 | Evenity | Romosozumab | Injection, Romosozumab-aqqg 1 mg | PA Request | 4/1/2023 | Osteoporosis |
| J1305 | Evkeeza | Evinacumab-Dgnb | Injection, Evinacumab-dgnb, 5mg | PA Request | 1/1/2024 | Hypercholesterolemia |
| J1428 | Exondys 51 | Eteplirsen | Injection, Eteplirsen, 10 mg | PA Request | 1/1/2023 | Duchenne Muscular Dystrophy (DMD) |
| J0178 | Eylea | Aflibercept | Injection, Aflibercept, 1 mg | PA Request | 4/1/2023 | Macular Degeneration |
| Q0138, Q0139 | Feraheme | Ferumoxytol | Injection, Ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | No PA/No Precert Required | N/A | Anemia |
| J2916 | Ferlecit | Sodium Ferric Gluconate | Injection, Sodium Ferric Gluconate complex in sucrose injection, 12.5 mg | No PA/No Precert Required | N/A | Anemia |
| J0517 | Fasenra | Benralizumab | Injection, Benralizumab, 1 mg | PA Request | 4/1/2023 | Asthma |
| Q5130 | Flynetra | Pegfilgrastim-pbbk | Injection, Pegfilgrastim-pbbk (Flynetra), biosimilar, 0.5 mg | No PA/No Precert Required | N/A | Neutropenia |
| J9155 | Firmagon | Degarelix | Injection, Degarelix, 1 mg | PA Request | 4/1/2023 | Oncology |
| J9307 | Foloty | Pralatrexate | Injection, Pralatrexate, 1 mg | PA Request | 4/1/2023 | Oncology |
| Q5108 | Fulphila | Pegfilgrastim-Jmdb | Injection, Pegfilgrastim-jmdb (Fulphila), biosimilar, 0.5 mg | PA Request | 8/1/2023 | Neutropenia |
| J1561 | Gammaked | immune globulin | Injection, immune globulin, (gamunexc/gammaked), non-lyophilized (e. g., liquid), 500 mg | PA Request | 6/1/2024 | Immunodeficiency |
| J1561 | Gamunex-C | immune globulin | Injection, immune globulin, (gamunexc/gammaked), non-lyophilized (e. g., liquid), 500 mg | PA Request | 6/1/2024 | Immunodeficiency |
| J9301 | Gazyva | Obinutuzumab | Injection, Obinutuzumab, 10 mg | PA Request | 4/1/2023 | Oncology |
| J7326 | Gel-One | Hyaluronan Or Derivative | Hyaluronan or derivative, Gel-one, for intra-articular injection, per dose | PA Request | 4/1/2023 | Osteoarthritis |
| J7328 | Gelsyn-3 | Hyaluronan Or Derivative | Hyaluronan or derivative, Gelsyn-3, for intra-articular injection, 0.1 mg | PA Request | 4/1/2023 | Osteoarthritis |
| J7320 | Genvisc 850 | Hyaluronan Or Derivative | Hyaluronan or derivative, Genvisc 850, for intra-articular injection, 1 mg | PA Request | 4/1/2023 | Osteoarthritis |
| J1447 | Granix | Tbo-filgrastim | Injection, Tbo-filgrastim, 1 microgram | PA Request | 11/1/2023 | Neutropenia |
| J9179 | Halaven | Eribulin Mesylate | Injection, Eribulin mesylate, 0.1 mg | PA Request | 4/1/2023 | Oncology |
| J7170 | Hemlibra | Emicizumab | Injection, Emicizumab-kxwh, 0.5 mg | PA Request | 4/1/2023 | Hemophilia |
| J9355 | Herceptin | Trastuzumab | Injection, Trastuzumab, excludes biosimilar, 10 mg | PA Request | 4/1/2023 | Oncology |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|-----------------------------------|--------------------------------|--|---------------------------|----------------------------|------------------------------|
| Q5113 | Herzuma | Trastuzumab-pkrb | Injection, Trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9356 | Herceptin Hylecta | Trastuzumab/Hyaluronidase-Oysk | Injection, Trastuzumab, 10 mg and hyaluronidase-oysk | PA Request | 4/1/2023 | Oncology |
| J1559 | Hizentra | Immune Globulin | Injection, Immune Globulin (Hizentra), 100 mg | PA Request | 1/1/2024 | Immunodeficiency |
| J7321 | Hyalgan | Hyaluronan or derivative | Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose | No PA/No Precert Required | N/A | Osteoarthritis |
| J0135 | Humira | Adalimumab | Injection, Adalimumab, 20 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J7322 | Hymovis | Hyaluronan Or Derivative | Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg | PA Request | 4/1/2023 | Osteoarthritis |
| J1575 | Hyqvia | Immune Globulin | Injection, Immune Globulin/Hyaluronidase, (Hyqvia), 100 mg | PA Request | 1/1/2024 | Immunodeficiency |
| J0638 | Ilaris | Canakinumab | Injection, Canakinumab, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J3245 | Ilumya | Tildrakizumab | Injection, Tildrakizumab, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J7313 | Iluvien | Fluocinolone Acetonide | Injection, Fluocinolone Acetonide intravitreal implant, 0.01 mg | PA Request | 4/1/2023 | Ophthalmic Disorders |
| J9173 | Imfinzi | Durvalumab | Injection, Durvalumab, 10 mg | PA Request | 4/1/2023 | Oncology |
| J9347 | Imjudo | Tremelimumab-Actl | Injection, Tremelimumab-actl, 1 mg | PA Request | 1/1/2024 | Oncology |
| J1750 | Infed | Iron Dextran | Injection, Iron Dextran, 50 mg | No PA/No Precert Required | N/A | Anemia |
| J9325 | Imlygic | Talimogene Laherparepvec | Injection, Talimogene Laherparepvec, per 1 million plaque forming units | PA Request | 1/1/2023 | Auto-Inflammatory Conditions |
| Q5103 | Inflectra | Infliximab–Dyyb | Injection, Infliximab-Dyyb, biosimilar, (Inflectra), 10 mg | PA Request | 8/1/2023 | Auto-Inflammatory Conditions |
| Q5109 | Ixifi | Infliximab-qbtx | Injection, Infliximab-qbtx, biosimilar, (Ixifi), 10 mg | No PA/No Precert Required | N/A | Auto-inflammatory Conditions |
| J1439 | Injectafer | Ferric Carboxymaltose | Injection, Ferric Carboxymaltose, 1 mg | PA Request | 4/1/2023 | Anemia |
| Q5117 | Kanjinti | Trastuzumab-anns | Injection, Trastuzumab-anns, biosimilar, (Kanjinti), 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9354 | Kadcyla | Ado-Trastuzumab Emtansine | Injection, Ado-trastuzumab emtansine, 1 mg | PA Request | 4/1/2023 | Oncology |
| J2425 | Kepivance | Palifermin | Injection, Palifermin 50 mg | PA Request | 4/1/2023 | Oncology |
| J9271 | Keytruda | Pembrolizumab | Injection, Pembrolizumab, 1 mg | PA Request | 4/1/2023 | Oncology |
| J9274 | Kimmtrak | Tebentafusp-tebn | Inj, Tebentafusp-tebn, 1 mcg | PA Request | 11/1/2023 | Oncology |
| J0879 | Korsuva | Difelikefalin | Injection, Difelikefalin, 0.1 microgram | PA Request | 1/1/2024 | Itching associated with CKD |
| J2507 | Krystexxa | Pegloticase | Injection, Pegloticase, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|------------------------------------|-----------------------------|---|---------------------------|----------------------------|----------------------------|
| J1626 | Kytril | Granisetron hydrochloride | Injection, Granisetron hydrochloride, 100 mcg | No PA/No Precert Required | N/A | Anti-emetics |
| J1932 | Lanreotide | Lanreotide | Injection, Lanreotide, (Cipla), 1 mg | No PA/No Precert Required | N/A | Endocrine Disorders |
| J0174 | Legembi | Lecanemab | Injection, lecanemab-irmb, 1mg | PA Request | 6/1/2024 | Antidementia Agent |
| J9047 | Kyprolis | Carfilzomib | Injection, Carfilzomib, 1 mg | PA Request | 4/1/2023 | Oncology |
| J0202 | Lemtrada | Alemtuzumab | Injection, Alemtuzumab, 1 mg | PA Request | 4/1/2023 | Multiple Sclerosis |
| J1306 | Leqvio | Inclisiran | Injection, Inclisiran, 1 mg | PA Request | 4/1/2023 | Hypercholesterolemia |
| J1954 | Leuprolide Acetate | Leuprolide Acetate | Injection, Leuprolide Acetate for depot suspension (lutrate), 7.5 mg | PA Request | 8/1/2023 | Oncology |
| J9119 | Libtayo | Cemiplimab-Rwlc | Injection, Cemiplimab-rwlc, 1 mg | PA Request | 4/1/2023 | Oncology |
| J2778 | Lucentis | Ranibizumab | Injection, Ranibizumab, 0.1 mg | PA Request | 4/1/2023 | Macular Degeneration |
| J0221 | Lumizyme | Alglucosidase Alfa | Injection, Alglucosidase alfa, (Lumizyme), 10 mg | PA Request | 4/1/2023 | Enzyme Deficiency |
| J9350 | Lunsumio | Mosunetuzumab-Axgb | Injection, Mosunetuzumab-axgb, 1 mg | PA Request | 1/1/2024 | Oncology |
| J1950 | Lupron Depot | Leuprolide Acetate | Injection, Leuprolide acetate (for depot suspension), per 3.75 mg | PA Request | 4/1/2023 | Oncology |
| J9217 | Lupron Depot | Leuprolide Acetate | Injection, Leuprolide acetate (for depot suspension), per 3.75 mg | PA Request | 11/1/2023 | Oncology |
| J3398 | Luxturna | Voretigene Neparvovec | Injection, Voretigene Neparvovec-rzyl, 1 billion vector genomes | PA Request | 4/1/2023 | Leber Congenital Amaurosis |
| J2503 | Macugen | Pegaptanib | Injection, Pegaptanib sodium, 0.3 mg | PA Request | 4/1/2023 | Macular Degeneration |
| J9349 | Monjuvi | Tafasitamab-Cxix | Injection, Tafasitamab-cxix | PA Request | 4/1/2023 | Oncology |
| J1437 | Monoferric | Ferric Derisomaltose | Injection, Ferric Derisomaltose, 10 mg | PA Request | 4/1/2023 | Anemia |
| J7327 | Monovisc | Hyaluronan Or Derivative | Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose | PA Request | 4/1/2023 | Osteoarthritis |
| Q5107 | Mvasi | Bevacizumab-Awwb | Injection, Bevacizumab-awwb, biosimilar, (Mvasi), 10 mg | PA Request | 8/1/2023 | Oncology |
| J9203 | Mylotarg | Gemtuzumab Ozogamicin | Injection, Gemtuzumab ozogamicin, 0.1 mg | PA Request | 11/1/2023 | Oncology |
| J0587 | Myobloc | Rimabotulinumtoxinb | Injection, Rimabotulinumtoxinb, 100 units | PA Request | 4/1/2023 | Neurotoxin |
| J7330 | N/A | MACI implant | Autologous Cultured Chondrocytes, implant | PA Request | 1/1/2023 | Osteoarthritis |
| Q4082 | N/A | Misc | Drug or Biological, not otherwise classified, Part B Drug Competitive Acquisition Program (CAP) | PA Request | 1/1/2023 | Misc |
| J9314 | N/A | Pemetrexed (Teva) | Injection, Pemetrexed (Teva) not therapeutically equivalent to J9305, 10 mg | PA Request | 8/1/2023 | Oncology |
| J9048 | N/A | Bortezomib (Fresenius Kabi) | Injection, Bortezomib (Fresenius Kabi), not therapeutically equivalent to j9041, 0.1 mg | PA Request | 8/1/2023 | Oncology |
| J9049 | N/A | Bortezomib (Hospira) | Injection, Bortezomib (Hospira), not therapeutically equivalent to j9041, 0.1 mg | PA Request | 8/1/2023 | Oncology |
| J9046 | N/A | Bortezomib (Dr. Reddy's) | Injection, Bortezomib, (Dr. Reddy's), not therapeutically equivalent to j9041, 0.1 mg | PA Request | 8/1/2023 | Oncology |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|----------------------------|-------------------------------|--|---------------------------|----------------------------|------------------------------|
| J0893 | N/A | Decitabine (Sun) | Injection, Decitabine (Sun Pharma) not therapeutically equivalent to j0894, 1 mg | PA Request | 8/1/2023 | Oncology |
| J9394 | N/A | Fulvestrant (Fresenius) | Injection, Fulvestrant (Fresenius Kabi) not therapeutically equivalent to j9395, 25 mg | PA Request | 8/1/2023 | Oncology |
| J9393 | N/A | Fulvestrant (Teva) | Injection, Fulvestrant (Teva) not therapeutically equivalent to j9395, 25 mg | PA Request | 8/1/2023 | Oncology |
| J1458 | Naglazyme | Galsulfase | Injection, Galsulfase, 1 mg | PA Request | 4/1/2023 | Enzyme Deficiency |
| J2506 | Neulasta | Pegfilgrastim | Injection, Pegfilgrastim, excludes biosimilar, 0.5 mg | PA Request | 4/1/2023 | Neutropenia |
| J1442 | Neupogen | Filgrastim | Injection, Filgrastim (G-CSF), (Neupogen) excludes biosimilars, 1 mcg | PA Request | 4/1/2023 | Neutropenia |
| J0219 | Nexviazyme | Avalglucosidase Alfa-Ngpt | Injection, Avalglucosidase alfa-ngpt, 4 mg | PA Request | 4/1/2023 | Enzyme Deficiency |
| Q5110 | Nivestym | Filgrastim-Aafi | Injection, Filgrastim-aafi, biosimilar, (Nivestym), 1 microgram | PA Request | 8/1/2023 | Neutropenia |
| J3490 | Not Otherwise Classified | Unclassified drugs | Drugs Unclassified injection | PA Request | 4/1/2023 | Misc |
| J3590 | Not Otherwise Classified | Unclassified biologics | Unclassified Biologics | PA Request | 1/1/2023 | Misc |
| J2796 | Nplate | Romiplostim | Injection, Romiplostim, 10 mg | PA Request | 4/1/2023 | Thrombocytopenia |
| J2182 | Nucaia | Mepolizumab | Injection, Mepolizumab, 1 mg | PA Request | 4/1/2023 | Asthma |
| J0485 | Nulojix | Belatacept | Injection, Belatacept, 1 mg | PA Request | 4/1/2023 | Immunosuppressive Agent |
| Q5122 | Nyvepria | Pegfilgrastim-Apgf | Injection, Pegfilgrastim-apgf (Nyvepria), biosimilar, 0.5 mg | PA Request | 8/1/2023 | Neutropenia |
| J2350 | Ocrevus | Ocrelizumab | Injection, Ocrelizumab, 1 mg | PA Request | 4/1/2023 | Multiple Sclerosis |
| Q5114 | Ogivri | Trastuzumab-Dkst | Injection, Trastuzumab-dkst, biosimilar, (ogivri), 10 mg | No PA/No Precert Required | N/A | Oncology |
| J0222 | Onpattro | Patisiran | Injection, Patisiran, 0.1 mg | PA Request | 11/1/2023 | Amyloidosis |
| Q5112 | Ontruzant | Trastuzumab-Dttb | Injection, Trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9299 | Opdivo | Nivolumab | Injection, Nivolumab, 1 mg | PA Request | 4/1/2023 | Oncology |
| J9298 | Opdualag | Nivolumab and Relatlimab-Rmbw | Injection, Nivolumab and Relatlimab-rmbw, 3 mg/1 mg | PA Request | 1/1/2024 | Oncology |
| J0129 | Orencia | Abatacept | Injection, Abatacept, 10 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J7324 | Orthovisc | Hyaluronan Or Derivative | Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose | PA Request | 4/1/2023 | Osteoarthritis |
| J9294 | Pemetrexed | Pemetrexed | Injection, Pemetrexed (Hospira), not therapeutically equivalent to J9305, 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9296 | Pemetrexed | Pemetrexed | Injection, Pemetrexed (Accord), not therapeutically equivalent to J9305, 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9297 | Pemetrexed | Pemetrexed | Injection, Pemetrexed (Sandoz), not therapeutically equivalent to J9305, 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9306 | Perjeta | Pertuzumab | Injection, Pertuzumab, 1 mg | PA Request | 4/1/2023 | Oncology |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|--------------|---------------------------------|---|--|---------------------------|----------------------------|-------------------------------------|
| J9316 | Phesgo | Pertuzumab/Trastuzumab/Hyaluronidase-Zzxf | Injection, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, per 10 mg | PA Request | 4/1/2023 | Oncology |
| J9204 | Poteligeo | Mogamulizumab-Kpkc | Injection, Mogamulizumab-kpkc, 1 mg | PA Request | 4/1/2023 | Oncology |
| J1459 | Privigen | immune globulin | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | PA Request | 6/1/2024 | Immunodeficiency |
| Q4081 | Procrit | Epoetin alfa | Injection, Epoetin alfa, 100 units (for esrd on dialysis) | PA Request | 11/1/2023 | Anemia (Dialysis) |
| J0897 | Prolia | Denosumab | Injection, Denosumab, 1 mg | PA Request | 4/1/2023 | Osteoporosis |
| J1301 | Radicava | Edaravone | Injection, Edaravone, 1 mg | PA Request | 4/1/2023 | Amyotrophic Lateral Sclerosis (ALS) |
| J0896 | Reblozyl | Luspatercept-Aamt | Injection, Luspatercept-aamt 0.25mg | PA Request | 4/1/2023 | Myelodysplastic Syndrome (MDS) |
| J3489 | Reclast | Zoledronic Acid | Injection, Zoledronic Acid, 1 mg | No PA/No Precert Required | N/A | Endocrine Disorders |
| Q5125 | Releuko | Filgrastim-Ayow | Injection, Filgrastim-ayow, biosimilar, (Releuko), 1 microgram | No PA/No Precert Required | N/A | Neutropenia |
| J1745 | Remicade | Infliximab | Injection, Infliximab, excludes biosimilar, 10 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| Q5104 | Renflexis | Infliximab-Abda | Injection, Infliximab-Abda, biosimilar, (Renflexis), 10 mg | PA Request | 8/1/2023 | Auto-Inflammatory Conditions |
| Q5105, Q5106 | Retacrit | Epoetin Alfa-Epbx | Injection, Epoetin alfa-epbx, biosimilar, (Retacrit) (for esrd on dialysis), 100 units | No PA/No Precert Required | N/A | Anemia |
| Q5123 | Riabni | Rituximab-Arrx | Injection, Rituximab-arrx, biosimilar, (Riabni), 10 mg | PA Request | 8/1/2023 | Oncology |
| J9312 | Rituxan | Infliximab | Injection, Rituximab, 10 mg | PA Request | 4/1/2023 | Oncology |
| J9311 | Rituxan Hycela | Rituximab/Hyaluronidase | Injection, Rituximab 10 mg and hyaluronidase | PA Request | 4/1/2023 | Oncology |
| J1449 | Rolvecon | Eflapegrastim-Xnst | Injection, Eflapegrastim-xnst, 0.1 mg | PA Request | 1/1/2024 | Neutropenia |
| Q5119 | Ruxience | Rituximab-Pvvr | Injection, Rituximab-pvvr, biosimilar, (Ruxience), 10 mg | PA Request | 8/1/2023 | Oncology |
| J9061 | Rybrevant | Amivantamab | Injection, Amivantamab-vmjw, 2 mg | PA Request | 1/1/2024 | Oncology |
| J9021 | Rylaze | Asparaginase Erwinia Chrysanthemii (recombinant)-rywn | Injection, Asparaginase, recombinant, (Rylaze), 0.1 mg | PA Request | 1/1/2024 | Oncology |
| J2998 | Ryplazim | Plasminogen, Human-Tvmh | Injection, plasminogen, human-tvmh, 1 mg | PA Request | 4/1/2023 | Hypoplasminogenemia |
| J2353 | Sandostatin LAR | Octreotide | Injection, Octreotide, Depot Form for Intramuscular Injection, 1 Mg | PA Request | 4/1/2023 | Endocrine Disorders |
| J0491 | Saphnelo | Anifrolumab-Fnia | Injection, Anifrolumab-fnia, 1 mg | PA Request | 1/1/2024 | Systemic Lupus Erythematosus (SLE) |
| J9227 | Sarclisa | Isatuximab-irfc | Injection, Isatuximab-irfc, 10 mg | PA Request | 11/1/2023 | Oncology |
| J1602 | Simponi Aria | Golimumab | Injection, Golimumab, 1 mg, for intravenous use | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|----------------------------------|--------------------------------|--|---------------------------|----------------------------|------------------------------|
| J2327 | Skyrizi | Risankizumab | Injection, Risankizumab-rzaa, intravenous, 1 mg | PA Request | 8/1/2023 | Auto-Inflammatory Conditions |
| J7331 | Sodium Hyaluronate | Hyaluronan or derivative | Hyaluronan or derivative, Synojoynt, for intra-articular injection, 1 mg | No PA/No Precert Required | N/A | Osteoarthritis |
| J1300 | Soliris | Eculizumab | Injection, Eculizumab, 10 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J1930 | Somatuline Depot | Lanreotide | Injection, Lanreotide, 1 mg | PA Request | 4/1/2023 | Endocrine Disorders |
| J1747 | Spevigo | Spesolimab-Sbzo | Injection, Spesolimab-sbzo | PA Request | 1/1/2024 | Auto-Inflammatory Conditions |
| J2326 | Spinraza | Nusinersen | Injection, Nusinersen, 0.1 mg | PA Request | 4/1/2023 | Spinal Muscular Atrophy |
| J3358 | Stelara IV | Ustekinumab | Ustekinumab, for intravenous injection, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J3357 | Stelara SC | Ustekinumab | Ustekinumab, for subcutaneous injection, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| Q5127 | Stimufend | Pegfilgrastim-Fpgk | Injection, Pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg | No PA/No Precert Required | N/A | Neutropenia |
| J7321 | Supartz-FX | Hyaluronan or derivative | Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose | No PA/No Precert Required | N/A | Osteoarthritis |
| J1627 | Sustol | Granisetron (Extended-Release) | Injection, Granisetron, extended-release, 0.1 mg | PA Request | 4/1/2023 | Anti-emetic |
| J7331 | Synojoynt | Hyaluronan or derivative | Hyaluronan or derivative, Synojoynt, for intra-articular injection, 1 mg | No PA/No Precert Required | N/A | Osteoarthritis |
| J7325 | Synvisc | Hyaluronan or derivative | Hyaluronan or derivative, Synvisc or Synvisc-one, for intra-articular injection, 1 mg | No PA/No Precert Required | N/A | Osteoarthritis |
| J7325 | Synvisc-One | Hyaluronan or derivative | Hyaluronan or derivative, Synvisc or Synvisc-one, for intra-articular injection, 1 mg | No PA/No Precert Required | N/A | Osteoarthritis |
| J9022 | Tecentrig | Atezolizumab | Injection, Atezolizumab, 10 mg | PA Request | 4/1/2023 | Oncology |
| J9380 | Tecvyli | Teclistamab Cqyv | Injection, Teclistamab-cqyv, 0.5 mg | PA Request | 1/1/2024 | Oncology |
| J3241 | Tepezza | Teprotumumab-Trbw | Injection, Teprotumumab-trbw, 10 mg | PA Request | 4/1/2023 | Thyroid Eye Disease (TED) |
| J2356 | Tezspire | Tezepelumab-Ekko | Injection, Tezepelumab-ekko, 1 mg | PA Request | 4/1/2023 | Asthma |
| J9273 | Tivdak | Tisotumab Vedodin-Tftv | Injection, Tisotumab Vedotin-tftv | PA Request | 1/1/2024 | Oncology |
| Q5116 | Trazimera | Trastuzumab-Qyyp | Injection, Trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | No PA/No Precert Required | N/A | Oncology |
| J9033 | Treanda | Bendamustine | Injection, Bendamustine hcl (Treanda), 1 mg | PA Request | 4/1/2023 | Oncology |
| J3315 | Trelstar | Triptorelin Pamoate | Injection, Triptorelin Pamoate 3.75 mg (Trelstar) | PA Request | 4/1/2023 | Oncology |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|-----------------------------------|------------------------------|--|---------------------------|----------------------------|-----------------------------------|
| J1628 | Tremfya | Guselkumab | Injection, Guselkumab, 1 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J1443 | Triferic | Ferric Pyrophosphate Citrate | Injection, Ferric Pyrophosphate citrate solution (triferic), 0.1 mg of iron | No PA/No Precert Required | N/A | Anemia |
| J1444 | Triferic | Ferric Pyrophosphate Citrate | Injection, Ferric Pyrophosphate citrate powder, 0.1 mg of iron | No PA/No Precert Required | N/A | Anemia |
| J1445 | Triferic AVNU | Ferric Pyrophosphate Citrate | Injection, Ferric Pyrophosphate citrate solution (Triferic Avnu), 0.1 mg of iron | No PA/No Precert Required | N/A | Anemia |
| J7332 | Triluron | Hyaluronan Or Derivative | Hyaluronan or derivative, Triluron, for intra-articular injection, 1 mg | PA Request | 4/1/2023 | Osteoarthritis |
| J3316 | Triptodur | Triptorelin | Injection, Triptorelin, extended-release, 3.75 mg | PA Request | 4/1/2023 | Oncology |
| J7329 | Trivisc | Hyaluronan Or Derivative | Hyaluronan or derivative, Trivisc, for intra-articular injection, 1 mg | PA Request | 4/1/2023 | Osteoarthritis |
| J9317 | Trodely | Sacituzumab Govitecan-Hziy | Injection, Sacituzumab Govitecan-Hziy, 2.5 Mg | PA Request | 4/1/2023 | Oncology |
| J1746 | Trogarzo | Ibalizumab-uiyk | Injection, Ibalizumab-uiyk, 10 mg | PA Request | 11/1/2023 | HIV/AIDS |
| Q5115 | Truxima | Rituximab-Abbs | Injection, Rituximab-abbs, biosimilar, (Truxima), 10 mg | PA Request | 8/1/2023 | Oncology |
| J2323 | Tysabri | Natalizumab | Injection, Natalizumab, 1 mg | PA Request | 4/1/2023 | Multiple Sclerosis |
| Q5111 | Udenyca | Pegfilgrastim-Cbqv | Injection, Pegfilgrastim-cbqv (Udenyca), biosimilar, 0.5 mg | PA Request | 8/1/2023 | Neutropenia |
| J1303 | Ultomiris | Ravulizumab | Injection, Ravulizumab-cwvz, 10 mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J9399 | Unclassified Drugs or Biologicals | Chemotherapy Drugs | Chemotherapy Drugs | PA Request | 1/1/2023 | Oncology |
| J1823 | Uplizna | Inebilizumab-Cdon | Injection, Inebilizumab-cdon, 1 Mg | PA Request | 4/1/2023 | Auto-Inflammatory Conditions |
| J2777 | Vabysmo | Faricimab-Svoa | Injection, Faricimab-svoa, 0.1 mg | PA Request | 1/1/2024 | Macular Degeneration |
| J9303 | Vectibix | Panitumumab | Injection, Panitumumab, 10 mg | PA Request | 4/1/2023 | Oncology |
| Q5129 | Vegzelma | Bevacizumab-Adcd | Injection, Bevacizumab-adcd (Vegzelma), biosimilar, 10 mg | PA Request | 8/1/2023 | Oncology |
| J9041 | Velcade | Bortezomib | Injection, Bortezomib (Velcade), 0.1 mg | PA Request | 4/1/2023 | Oncology |
| J1756 | Venofer | Iron Sucrose | Injection, Iron Sucrose, 1 mg | No PA/No Precert Required | N/A | Anemia |
| J1427 | Viltepto | Viltolarsen | Injection, Viltolarsen, 10 mg | PA Request | 1/1/2023 | Duchenne Muscular Dystrophy (DMD) |
| J7321 | Visco-3 | Hyaluronan or derivative | Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose | No PA/No Precert Required | N/A | Osteoarthritis |
| J3396 | Visudyne | Verteporfin | Injection, Verteporfin, 0.1 Mg | PA Request | 4/1/2023 | Ophthalmic Disorders |
| J3385 | Vpriv | Velaglucerase Alfa | Injection, Velaglucerase alfa, 100 units | PA Request | 4/1/2023 | Enzyme Deficiency |
| J3032 | Vyepi | Eptinezumab | Injection, Eptinezumab-jjmr, 1 mg | PA Request | 4/1/2023 | Neurotoxin |

Ascension Personalized Care

| HCPCS code | Brand Name | Generic Name | HCPCS Description | Requirement | Requirement Effective Date | Clinical Category |
|------------|----------------------------|---------------------------------------|--|---------------------------|----------------------------|--|
| J1429 | Vyondys 53 | Golodirsen | Injection, Golodirsen, 10 mg | PA Request | 1/1/2023 | Duchenne Muscular Dystrophy (DMD) |
| J9332 | Vyvgart | Efgartigimod Alfa-Fcab | Injection, Efgartigimod Alfa-fcab, 2mg | PA Request | 1/1/2024 | Myasthenia Gravis (MG) |
| J1558 | Xembify | Immune Globulin | Injection, Immune Globulin (Xembify), 100 mg | PA Request | 1/1/2024 | Immunodeficiency |
| J0218 | Xenpozyme | Olipudase Alfa-Rpcp | Injection, Olipudase Alfa-rpcp, 1 mg | PA Request | 1/1/2024 | Enzyme Deficiency |
| J0588 | Xeomin | Incobotulinumtoxin A | Injection, Incobotulinumtoxin a, 1 unit | PA Request | 4/1/2023 | Neurotoxin |
| J0775 | Xiaflex | Collagenase, Clostridium Histolyticum | Injection, Collagenase, clostridium histolyticum, 0.01 mg | PA Request | 4/1/2023 | Enzyme |
| J2357 | Xolair | Omalizumab | Injection, Omalizumab, 5 mg | PA Request | 4/1/2023 | Asthma |
| J9228 | Yervoy | Ipilimumab | Injection, Ipilimumab, 1 mg | PA Request | 4/1/2023 | Oncology |
| Q5101 | Zarxio | Filgrastim-Sndz | Injection, Filgrastim-sndz, biosimilar, (Zarxio) 1 microgram | PA Request | 8/1/2023 | Neutropenia |
| J9223 | Zepzelca | Lurbinectedin | Injection, Lurbinectedin, 0.1 Mg | PA Request | 4/1/2023 | Oncology |
| Q5120 | Ziextenzo | Pegfilgrastim-Bmez | Injection, Pegfilgrastim-bmez, (Ziextenzo), biosimilar, 0.5 mg | PA Request | 8/1/2023 | Neutropenia |
| J0565 | Zinplava | Bezlotoxumab | Injection, Bezlotoxumab, 10 mg | PA Request | 4/1/2023 | Passive Immunizing and Treatment Agent |
| Q5118 | Zirabev | Bevacizumab-Bvzr | Injection, Bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg | PA Request | 8/1/2023 | Oncology |
| J2405 | Zofran | Ondansetron | Injection, Ondansetron hydrochloride | No PA/No Precert Required | N/A | Anti-emetics |
| J9202 | Zoladex | Goserelin Acetate | Goserelin acetate | PA Request | 1/1/2024 | Oncology |
| J3489 | Zoledronic Acid | Zoledronic Acid | Injection, Zoledronic Acid, 1 mg | No PA/No Precert Required | N/A | Endocrine Disorders |
| J3399 | Zolgensma | Onasemnogene Abeparvovec | Injection, Onasemnogene Abeparvovec-xioi, per treatment, up to 5x10 ¹⁵ vector genomes | PA Request | 4/1/2023 | Spinal Muscular Atrophy |
| J9359 | Zynlonta | Loncastuximab Tesirine-Lpyl | Injection, Loncastuximab Tesirine-lpyl, 0.075 mg | PA Request | 1/1/2024 | Oncology |